ABBV vs NKE: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and NIKE, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
NIKE, Inc. · Consumer Cyclical
$42.62
+45.5% upside to fair value
Med Conviction
Grade B+
QuantHub Verdict
NKE has more upside to fair value
(+45.5%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
NKE |
| Current Price |
$208.05 |
$42.62 |
| Fair Value Estimate |
$217.50 |
$62.00 |
| Upside to Fair Value |
+4.5%
|
+45.5%
|
| Market Cap |
$367.9B |
$63.0B |
| Forward P/E |
14.9x
|
27.9x
|
| EV / EBITDA |
16.7x
|
20.7x
|
| Price / Sales |
6.1x
|
1.4x
|
| Price / FCF |
20.9x
|
19.4x
|
| Revenue Growth YoY |
+8.6%
|
-9.8%
|
| Gross Margin |
83.7%
|
42.7%
|
| Operating Margin |
34.7%
|
8.0%
|
| Return on Equity |
-129.24%
|
24.4%
|
| Dividend Yield |
3.2% |
3.8% |
| FCF Yield |
4.78%
|
5.2%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Nike is the world's largest athletic footwear and apparel company with $46.3B in FY2025 revenue, operating across 190+ countries with the Nike, Jordan, and Converse brands. The stock trades near its 9-year low at $42.62 after an 11% single-day crash following a Q3 FY2026 earnings report that showed 35% net income decline and weak Q4 guidance calling for a further 2-4% revenue decline. FY2025 reve…
Accumulation Zones
| Metric |
ABBV |
NKE |
| Zone Low |
$163.13 |
$44.00 |
| Zone High |
$184.88 |
$50.00 |
| In Buy Zone? |
No
|
Yes
|